scholarly journals Semi-quantitative measurements of chemokine receptor 4-targeted 68Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Qingqing Pan ◽  
Xinxin Cao ◽  
Yaping Luo ◽  
Jian Li ◽  
Fang Li
Keyword(s):  
Partial Response ◽  
Clinical Response ◽  
Fdg Pet ◽  
Response Assessment ◽  
Lymphoplasmacytic Lymphoma ◽  
Monoclonal Protein ◽  
Quantitative Measurements ◽  
Waldenstrom Macroglobulinemia ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Purpose 68Ga-pentixafor PET/CT was reported to have a high sensitivity in detecting tumor involvement of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) in our previous study. We aimed to further investigate the semi-quantitative measurements of 68Ga-pentixafor PET/CT in response assessment in WM/LPL. Methods Fifteen patients with WM/LPL were recruited in a prospective cohort study and underwent both 68Ga-pentixafor and 18F-FDG PET/CT at baseline and post-treatment. PET/CT-based responses were analyzed with semi-quantitative assessments of metabolic tumor volume (MTV) and total lesions glycolysis/uptake (TLGFDG and TLUCXCR4), and the correlation between PET/CT-based response and clinical response, monoclonal protein and IgM response was analyzed. Results After chemotherapy, 5 patients had complete response or very good partial response, 8 had partial response or minimal response and 2 had progressive disease. In quantitative analysis, 68Ga-pentixafor PET/CT-based response (measured in ∆TLUCXCR4%, ∆MTVCXCR4%, ∆SUVpeak%) showed a significant direct correlation with clinical response, monoclonal protein and IgM response (p < 0.01). However, 18F-FDG PET/CT-based response was independent from clinical response (p > 0.05). Conclusions The semi-quantitative measurements of 68Ga-pentixafor PET/CT outperformed 18F-FDG PET/CT in response assessment of WM/LPL.

Can 8 week 18F-FDG PET/CT predict clinical response in evaluation of bone metastases in breast cancer?

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12539-e12539
Author(s):  
Gurdip Kaur Azad ◽  
Francois Cousin ◽  
Angela Swampillai ◽  
Benjamin P Taylor ◽  
Ines Sandri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Clinical Response ◽  
Fdg Pet ◽  
De Novo ◽  
Metastatic Breast ◽  
Response Assessment ◽  
Endocrine Treatment ◽  
Pet Ct ◽  
Fdg Pet Ct

e12539 Background: 18F-FDG (fluorodeoxyglucose) PET/CT scan is widely used for staging and response assessment of metastatic breast cancer. However, the role of early treatment response assessment of bone metastases remains undefined and the optimal method not yet determined. Our hypothesis was that early 18F-FDG PET/CT can predict subsequent clinical response and our aim was to compare early 8 week 18F-FDG PET/CT with clinical response assessment up to 12 weeks in bone metastases following endocrine treatment. Methods: Eighteen patients starting endocrine treatment for de novo or progressive bone metastases were prospectively recruited. 18F-FDG PET/CT scans were performed before and 8 weeks after treatment. Percentage change in maximum SUV (SUVmax) from the same ≤ 5 index lesions was measured. Clinical response up to 12 weeks, (combination of CT/bone scintigraphy, patient symptoms, Ca-15.3), assessed by an oncologist blinded to PET imaging findings was used as a reference standard. Results: In the 4 patients with progressive disease (PD); SUVmax increased ( > 25%) in 2/20 (10%) and was stable in 15/20 (75%) lesions. Clinically, 2/4 (50%) patients had stable symptoms and 2/4 (50%) worsening bone pain at 8 and 12 weeks. Ca-153 increased ( > 40%) in 3/4 (75%) patients. Conventional imaging at 12 weeks showed PD in all 4 patients. In the 7 patients with clinical partial response (PR); SUVmax decreased ( < 25%) in 23/35 (66%) and remained stable in 10/35 (29%) lesions. Ca-153 decreased ( > 80%) in 4/7 (57%) patients. Clinically, symptoms remained stable or improved in 6/7 (86%) patients at 8 and 12 weeks. Conventional scanning at 3 months showed either PR (n = 3) or SD (n = 4). In the 7 patients with stable disease (SD); SUVmax remained unchanged in 15/27 (56%) and decreased in 12/27 (44%) lesions. Ca-153 showed minimal changes in 6/7 (86%) patients. Conventional scans showed SD in all 7 patients. Conclusions: Our data show that although 18F-FDG PET/CT is reliable at predicting PR or SD, it has poorer predictive ability for clinical PD in bone metastases at 8 weeks. Intra-patient heterogeneity of response between lesions is a common observation. Clinical trial information: 12/LO/1801.

scholarly journals Usefulness of 18f-FDG PET-CT in Staging, Restaging, and Response Assessment in Pediatric Rhabdomyosarcoma

Diagnostics ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 1112
Author(s):  
Davide Donner ◽  
Paola Feraco ◽  
Linda Meneghello ◽  
Barbara Rombi ◽  
Lorena Picori ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Pediatric Patients ◽  
Response Assessment ◽  
Response To Therapy ◽  
High Morbidity ◽  
European Guidelines ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Clinical Advances

Rhabdomyosarcoma is the most common soft-tissue sarcoma of childhood. Despite clinical advances, subsets of these patients continue to suffer high morbidity and mortality rates associated with their disease. Following the European guidelines for 18F-FDG PET and PET-CT imaging in pediatric oncology, the routine use of 18F-FDG PET-CT may be useful for patients affected by rhabdomyosarcoma, in staging, in the evaluation of response to therapy, and for restaging/detection of relapse. The European Pediatric Protocols are very old, and for staging and restaging, they recommend only radionuclide bone scan. The 18F-FDG PET-CT exam is listed as an optional investigation prescribed according to local availability and local protocols in the investigations panel required at the end of the treatment. We present two cases highlighting the usefulness of 18F-FDG PET-CT in managing pediatric patients affected by rhabdomyosarcoma, providing some bibliographic references.

PH-0040: A 6-point scale approach to 18F-FDG PET-CT for response assessment in HNSCC: a multicenter study

2020 ◽  
Vol 152 ◽  
pp. S11-S12
Author(s):  
P. Bonomo ◽  
A. Merlotti ◽  
S. Morbelli ◽  
V. Berti ◽  
C. Saieva ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Fdg Pet ◽  
Response Assessment ◽  
Point Scale ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct
Sign in / Sign up

Export Citation Format

Share Document